Organovo (NASDAQ:ONVO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO) in a report issued on Friday morning. The firm issued a sell rating on the medical research company’s stock.

Organovo Trading Down 4.4 %

NASDAQ:ONVO opened at $0.72 on Friday. The firm has a market cap of $10.35 million, a PE ratio of -0.45 and a beta of 0.68. The stock has a fifty day moving average price of $0.93 and a 200 day moving average price of $1.01. Organovo has a 12-month low of $0.72 and a 12-month high of $2.05.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.